98%
921
2 minutes
20
Hearing loss and individual differences in normal hearing both have a substantial genetic basis. Although many new genes contributing to deafness have been identified, very little is known about genes/variants modulating the normal range of hearing ability. To fill this gap, we performed a two-stage meta-analysis on hearing thresholds (tested at 0.25, 0.5, 1, 2, 4, 8 kHz) and on pure-tone averages (low-, medium- and high-frequency thresholds grouped) in several isolated populations from Italy and Central Asia (total N = 2636). Here, we detected two genome-wide significant loci close to PCDH20 and SLC28A3 (top hits: rs78043697, P = 4.71E-10 and rs7032430, P = 2.39E-09, respectively). For both loci, we sought replication in two independent cohorts: B58C from the UK (N = 5892) and FITSA from Finland (N = 270). Both loci were successfully replicated at a nominal level of significance (P < 0.05). In order to confirm our quantitative findings, we carried out RT-PCR and reported RNA-Seq data, which showed that both genes are expressed in mouse inner ear, especially in hair cells, further suggesting them as good candidates for modulatory genes in the auditory system. Sequencing data revealed no functional variants in the coding region of PCDH20 or SLC28A3, suggesting that variation in regulatory sequences may affect expression. Overall, these results contribute to a better understanding of the complex mechanisms underlying human hearing function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572074 | PMC |
http://dx.doi.org/10.1093/hmg/ddv279 | DOI Listing |
Cereb Cortex
August 2025
Department of Psychology, University of Lübeck, Ratzeburger Allee 160, Lübeck 23562, Germany.
The human auditory system must distinguish relevant sounds from noise. Severe hearing loss can be treated with cochlear implants (CIs), but how the brain adapts to electrical hearing remains unclear. This study examined adaptation to unilateral CI use in the first and seventh months after CI activation using speech comprehension measures and electroencephalography recordings, both during passive listening and an active spatial listening task.
View Article and Find Full Text PDFMol Biol Rep
September 2025
Cytogenetics and Molecular Genetics Lab, Pathology Unit, Medical Division (BARC Hospital), Bhabha Atomic Research Centre, Anushakti Nagar, Mumbai, India.
Background: Hearing loss (HL) is one of the most common congenital anomalies and is a complex etiologically diverse condition. Molecular genetic characterization of HL remains challenging owing to the high genetic heterogeneity. This study aimed to screen for potential disease-causing genetic variations in a cohort of Indian patients with congenital bilateral severe-to-profound sensorineural HL.
View Article and Find Full Text PDFBrain Behav
September 2025
Radiology Department, Yantaishan Hospital, Yantai, Shandong, China.
Objective: To investigate the characteristics of brain structures in patients with noise-induced hearing loss (NIHL) using source-based morphometry (SBM) and to evaluate the correlation between abnormal brain regions and clinical data.
Methods: High-resolution 3D T1 structural images were acquired from 81 patients with NIHL and 74 age- and education level-matched healthy controls (HCs). The clinical data of all subjects were collected, including noise exposure time, monaural hearing threshold weighted values (MTWVs), Mini-Mental State Examination (MMSE), and Hamilton Anxiety Scale (HAMA) scores.
MedComm (2020)
September 2025
modulates presynaptic Ca1.3 Ca channel function in inner hair cells (IHCs) and is required for indefatigable synaptic sound encoding. Biallelic variants in are associated with non-syndromic hearing loss (DFNB93).
View Article and Find Full Text PDFEClinicalMedicine
October 2025
Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, 686 Bay St., Toronto, Ontario, Canada.
Background: While testicular germ cell tumors (TGCT) survival exceeds 90%, many survivors of adult TGCT are at risk for treatment toxicities. Less is known about physical morbidities in children, adolescents, and young adults (CAYA) with TGCT.
Methods: We used the Pediatric Oncology Group of Ontario Networked Information System, the Initiative to Maximize Progress in Adolescent and Young Adult Cancer Therapy, and the Ontario Cancer Registry to identify all CAYA males diagnosed with TGCT from 1992 to 2021 at age 11-21 years in Ontario, Canada.